Buy & Sell Bristol-Myers Squibb Co (BMY) – Bristol-Myers Squibb Co Price Today
Aura AI Summary
Key Stats
- $121.42BMarket Cap
- HealthSector
- -10.74%3M Drawdown
- $157.36BEnterprise Value
- 4.24%Dividend Yield
- 92 daysTypical Hold Time
Bristol-Myers Squibb Co (BMY) is currently valued at a market capitalization of $121.42B, with an enterprise value of $157.36B. Over the past 52 weeks, Bristol-Myers Squibb Co has traded between a low of $42.6 and a high of $62.37, highlighting its annual price range. Over the past three months, Bristol-Myers Squibb Co has recorded a drawdown of -10.74%, reflecting recent price volatility. Bristol-Myers Squibb Co offers a dividend yield of 4.24%, with the most recent dividend of $0.63 paid on 02 Apr 26. On average, investors hold Bristol-Myers Squibb Co for approximately 92 days, indicating typical investor behavior on the platform.
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Most Recent News
SpaceX IPO could trigger up to $27B in forced ETF buying due to Nasdaq rule changes, sparking potential lawsuits.
SpaceX's upcoming IPO may cause forced ETF buying of $22-$27 billion as Nasdaq changes rules to fast-track the company's index inclusion. The Nasdaq 100 now allows new companies to join within 15 days if their market cap ranks in the top 40, removing...

Global Bioprocess Automation Software market to reach $6.19B by 2035 with 14% CAGR, driven by personalized medicine and scalable production.
The global Bioprocess Automation Software market, valued at $1.67 billion in 2025, is projected to grow to $6.19 billion by 2035 at a 14% CAGR. This growth is fueled by the increasing demand for personalized medicine, flexible manufacturing processes...

Microneedle drug delivery market to double to $14.37B by 2035, driven by pain-free therapies and vaccine tech.
The global microneedle drug delivery systems market is projected to grow from $7.04 billion in 2025 to $14.37 billion by 2035, at a CAGR of 7.4%. Growth is fueled by rising demand for minimally invasive, pain-free, and self-administered drug delivery...
